Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

A peptide containing the receptor binding site of insulin-like growth factor binding protein-2 enhances bone mass in ovariectomized rats.

Xi G, Wai C, Rosen CJ, Clemmons DR.

Bone Res. 2018 Aug 14;6:23. doi: 10.1038/s41413-018-0024-9. eCollection 2018.

2.

A Consensus Statement on acromegaly therapeutic outcomes.

Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A.

Nat Rev Endocrinol. 2018 Sep;14(9):552-561. doi: 10.1038/s41574-018-0058-5. Review.

PMID:
30050156
3.

Role of IGF-binding proteins in regulating IGF responses to changes in metabolism.

Clemmons DR.

J Mol Endocrinol. 2018 Jul;61(1):T139-T169. doi: 10.1530/JME-18-0016. Epub 2018 Mar 21. Review.

PMID:
29563157
4.

Growth Hormone Research Society perspective on biomarkers of GH action in children and adults.

Johannsson G, Bidlingmaier M, Biller BMK, Boguszewski M, Casanueva FF, Chanson P, Clayton PE, Choong CS, Clemmons D, Dattani M, Frystyk J, Ho K, Hoffman AR, Horikawa R, Juul A, Kopchick JJ, Luo X, Neggers S, Netchine I, Olsson DS, Radovick S, Rosenfeld R, Ross RJ, Schilbach K, Solberg P, Strasburger C, Trainer P, Yuen KCJ, Wickstrom K, Jorgensen JOL; Growth Hormone Research Society.

Endocr Connect. 2018 Mar;7(3):R126-R134. doi: 10.1530/EC-18-0047. Epub 2018 Feb 26. Review.

5.

Osteoblast-like MC3T3-E1 Cells Prefer Glycolysis for ATP Production but Adipocyte-like 3T3-L1 Cells Prefer Oxidative Phosphorylation.

Guntur AR, Gerencser AA, Le PT, DeMambro VE, Bornstein SA, Mookerjee SA, Maridas DE, Clemmons DE, Brand MD, Rosen CJ.

J Bone Miner Res. 2018 Jun;33(6):1052-1065. doi: 10.1002/jbmr.3390. Epub 2018 Mar 30.

PMID:
29342317
6.

DIAGNOSING AND MONITORING ENDOCRINE DYSFUNCTION, DIABETES, AND OBESITY IN A COHORT OF ADULT SURVIVORS OF CHILDHOOD CANCER.

Hudspeth VR, Gold SH, Clemmons DR.

Endocr Pract. 2017 Dec;23(12):1394-1401. doi: 10.4158/EP-2017-0033. Epub 2017 Nov 16.

PMID:
29144813
7.

Excellence in the treatment of patients with pituitary tumors.

Molitch ME, Findling JW, Clemmons DR.

Pituitary. 2018 Feb;21(1):107. doi: 10.1007/s11102-017-0848-0. No abstract available.

PMID:
29124563
8.

Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly.

van der Lely AJ, Gomez R, Pleil A, Badia X, Brue T, Buchfelder M, Burman P, Clemmons D, Ghigo E, Jørgensen JOL, Luger A, van der Lans-Bussemaker J, Webb SM, Strasburger CJ.

Pituitary. 2017 Dec;20(6):692-701. doi: 10.1007/s11102-017-0835-5.

9.

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

Clemmons DR, Miller S, Mamputu JC.

PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. eCollection 2017.

10.

Down-regulation of Insulin Receptor Substrate 1 during Hyperglycemia Induces Vascular Smooth Muscle Cell Dedifferentiation.

Xi G, Wai C, White MF, Clemmons DR.

J Biol Chem. 2017 Feb 3;292(5):2009-2020. doi: 10.1074/jbc.M116.758987. Epub 2016 Dec 21.

11.

ACCURATE DIAGNOSIS OF GROWTH HORMONE DEFICIENCY IN ADULTS: THE ONGOING CHALLENGE.

Clemmons DR.

Endocr Pract. 2016 Dec;22(12):1462-1464. No abstract available.

PMID:
27929680
12.

Changing of the Guard.

Wierman ME, Chin WW, Clemmons DR, Gagel RF, Larsen JL.

Endocr Rev. 2016 Feb;2016(1):1-2. doi: 10.1210/EDRV-ER.2015-1072.2016.1.test. No abstract available.

PMID:
27454359
13.

Role of IGF Binding Proteins in Regulating Metabolism.

Clemmons DR.

Trends Endocrinol Metab. 2016 Jun;27(6):375-391. doi: 10.1016/j.tem.2016.03.019. Epub 2016 Apr 23. Review.

PMID:
27117513
14.

Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations.

Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF, Chanson P, Chatelain P, Choong CS, Clemmons DR, Cohen LE, Cohen P, Frystyk J, Grimberg A, Hasegawa Y, Haymond MW, Ho K, Hoffman AR, Holly JM, Horikawa R, Höybye C, Jorgensen JO, Johannsson G, Juul A, Katznelson L, Kopchick JJ, Lee KO, Lee KW, Luo X, Melmed S, Miller BS, Misra M, Popovic V, Rosenfeld RG, Ross J, Ross RJ, Saenger P, Strasburger CJ, Thorner MO, Werner H, Yuen K.

Eur J Endocrinol. 2016 Jun;174(6):C1-8. doi: 10.1530/EJE-16-0111. Epub 2016 Mar 23.

15.

IRS-1 Functions as a Molecular Scaffold to Coordinate IGF-I/IGFBP-2 Signaling During Osteoblast Differentiation.

Xi G, Shen X, Rosen CJ, Clemmons DR.

J Bone Miner Res. 2016 Jun;31(6):1300-14. doi: 10.1002/jbmr.2791. Epub 2016 Feb 20.

16.

IGF-I and IGFBP-2 Stimulate AMPK Activation and Autophagy, Which Are Required for Osteoblast Differentiation.

Xi G, Rosen CJ, Clemmons DR.

Endocrinology. 2016 Jan;157(1):268-81. doi: 10.1210/en.2015-1690. Epub 2015 Nov 10.

17.

Changing of the Guard.

Wierman ME, Chin WW, Clemmons DR, Gagel RF, Larsen JL.

Endocr Rev. 2015 Aug;36(4):345-6. doi: 10.1210/EDRV-ER.2015-1072. No abstract available.

PMID:
26240982
18.

Hyperglycemia stimulates p62/PKCζ interaction, which mediates NF-κB activation, increased Nox4 expression, and inflammatory cytokine activation in vascular smooth muscle.

Xi G, Shen X, Wai C, Vilas CK, Clemmons DR.

FASEB J. 2015 Dec;29(12):4772-82. doi: 10.1096/fj.15-275453. Epub 2015 Jul 31.

19.

Igfbp2 Deletion in Ovariectomized Mice Enhances Energy Expenditure but Accelerates Bone Loss.

DeMambro VE, Le PT, Guntur AR, Maridas DE, Canalis E, Nagano K, Baron R, Clemmons DR, Rosen CJ.

Endocrinology. 2015 Nov;156(11):4129-40. doi: 10.1210/en.2014-1452. Epub 2015 Jul 31.

20.

Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet.

Nichols TC, Merricks EP, Bellinger DA, Raymer RA, Yu J, Lam D, Koch GG, Busby WH Jr, Clemmons DR.

PLoS One. 2015 Jul 6;10(7):e0132302. doi: 10.1371/journal.pone.0132302. eCollection 2015.

21.

Lou Underwood: in memoriam.

D'Ercole AJ, Clemmons D.

Growth Horm IGF Res. 2015 Apr;25(2):57-8. No abstract available.

PMID:
25811055
23.

Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.

Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP.

Gastroenterology. 2015 Apr;148(4):740-750.e2. doi: 10.1053/j.gastro.2015.01.037. Epub 2015 Jan 30.

24.

Blocking αVβ3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats.

Maile LA, Gollahon K, Wai C, Dunbar P, Busby W, Clemmons D.

J Diabetes Res. 2014;2014:421827. doi: 10.1155/2014/421827. Epub 2014 Oct 20.

25.

Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs.

Maile LA, Busby WH, Gollahon KA, Flowers W, Garbacik N, Garbacik S, Stewart K, Nichols T, Bellinger D, Patel A, Dunbar P, Medlin M, Clemmons D.

Endocrinology. 2014 Dec;155(12):4665-75. doi: 10.1210/en.2014-1318. Epub 2014 Aug 29.

26.

FGF-21 and skeletal remodeling during and after lactation in C57BL/6J mice.

Bornstein S, Brown SA, Le PT, Wang X, DeMambro V, Horowitz MC, MacDougald O, Baron R, Lotinun S, Karsenty G, Wei W, Ferron M, Kovacs CS, Clemmons D, Wan Y, Rosen CJ.

Endocrinology. 2014 Sep;155(9):3516-26. doi: 10.1210/en.2014-1083. Epub 2014 Jun 10.

27.

IGFBP-2 directly stimulates osteoblast differentiation.

Xi G, Wai C, DeMambro V, Rosen CJ, Clemmons DR.

J Bone Miner Res. 2014 Nov;29(11):2427-38. doi: 10.1002/jbmr.2282.

28.

Expert consensus document: A consensus on the medical treatment of acromegaly.

Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S; Acromegaly Consensus Group.

Nat Rev Endocrinol. 2014 Apr;10(4):243-8. doi: 10.1038/nrendo.2014.21. Epub 2014 Feb 25. Review.

PMID:
24566817
29.

Growth hormone should be used only for approved indications.

Clemmons DR, Molitch M, Hoffman AR, Klibanski A, Strasburger CJ, Kleinberg DL, Ho K, Webb SM, Bronstein MD, Bouillon R, Ben-Shlomo A, Hamrahian AH, Chanson P, Barkan AL, Merriam GR, Blackman MR, Salvatori R.

J Clin Endocrinol Metab. 2014 Feb;99(2):409-11. doi: 10.1210/jc.2013-4187. Epub 2013 Dec 11. No abstract available.

30.

The heparin-binding domains of IGFBP-2 mediate its inhibitory effect on preadipocyte differentiation and fat development in male mice.

Xi G, Solum MA, Wai C, Maile LA, Rosen CJ, Clemmons DR.

Endocrinology. 2013 Nov;154(11):4146-57. doi: 10.1210/en.2013-1236. Epub 2013 Aug 27.

31.
32.

Growth hormone in health and disease: Long-term GH therapy--benefits and unanswered questions.

Clemmons D.

Nat Rev Endocrinol. 2013 Jun;9(6):317-8. doi: 10.1038/nrendo.2013.68. Epub 2013 Mar 26. No abstract available.

PMID:
23529042
33.
34.

Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes.

Clemmons DR.

Endocrinol Metab Clin North Am. 2012 Jun;41(2):425-43, vii-viii. doi: 10.1016/j.ecl.2012.04.017. Review.

35.

Hyperglycemia enhances IGF-I-stimulated Src activation via increasing Nox4-derived reactive oxygen species in a PKCζ-dependent manner in vascular smooth muscle cells.

Xi G, Shen X, Maile LA, Wai C, Gollahon K, Clemmons DR.

Diabetes. 2012 Jan;61(1):104-13. doi: 10.2337/db11-0990. Epub 2011 Dec 6.

36.

Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation.

DeMambro VE, Maile L, Wai C, Kawai M, Cascella T, Rosen CJ, Clemmons D.

J Bone Miner Res. 2012 Feb;27(2):390-400. doi: 10.1002/jbmr.545. Erratum in: J Bone Miner Res. 2012 Jun;27(6):1436.

37.

IGF-I stimulates cooperative interaction between the IGF-I receptor and CSK homologous kinase that regulates SHPS-1 phosphorylation in vascular smooth muscle cells.

Radhakrishnan Y, Shen X, Maile LA, Xi G, Clemmons DR.

Mol Endocrinol. 2011 Sep;25(9):1636-49. doi: 10.1210/me.2011-0035. Epub 2011 Jul 28.

38.

Igf-I signaling in response to hyperglycemia and the development of diabetic complications.

Clemmons D, Maile L, Xi G, Shen X, Radhakrishnan Y.

Curr Diabetes Rev. 2011 Jul;7(4):235-45. Review.

PMID:
21707534
39.

Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells.

Ning J, Xi G, Clemmons DR.

Endocrinology. 2011 Aug;152(8):3143-54. doi: 10.1210/en.2011-0155. Epub 2011 Jun 14.

40.

An essential role for the association of CD47 to SHPS-1 in skeletal remodeling.

Maile LA, DeMambro VE, Wai C, Lotinun S, Aday AW, Capps BE, Beamer WG, Rosen CJ, Clemmons DR.

J Bone Miner Res. 2011 Sep;26(9):2068-81. doi: 10.1002/jbmr.441. Erratum in: J Bone Miner Res. 2011 Nov;26(11):2792. Lotinun, Sutada [added].

41.

Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline.

Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society.

J Clin Endocrinol Metab. 2011 Jun;96(6):1587-609. doi: 10.1210/jc.2011-0179.

PMID:
21602453
42.

IGF binding protein 3 exerts its ligand-independent action by antagonizing BMP in zebrafish embryos.

Zhong Y, Lu L, Zhou J, Li Y, Liu Y, Clemmons DR, Duan C.

J Cell Sci. 2011 Jun 1;124(Pt 11):1925-35. doi: 10.1242/jcs.082644. Epub 2011 May 10.

43.

Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis.

Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, Ho KK, Lamberts SW, Clemmons DR; HypoCCS International Advisory Board.

J Clin Endocrinol Metab. 2011 Jul;96(7):2255-61. doi: 10.1210/jc.2011-0448. Epub 2011 May 4.

PMID:
21543424
44.

AMP kinase signals the insulin-like growth factor system whether adequate nutrient is present to support an anabolic response.

Clemmons DR.

Cell Cycle. 2011 Apr 1;10(7):1017-8. Epub 2011 Apr 1. No abstract available.

PMID:
21430440
45.

The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton.

Kawai M, Breggia AC, DeMambro VE, Shen X, Canalis E, Bouxsein ML, Beamer WG, Clemmons DR, Rosen CJ.

J Biol Chem. 2011 Apr 22;286(16):14670-80. doi: 10.1074/jbc.M110.193334. Epub 2011 Mar 3. Erratum in: J Biol Chem. 2011 Dec 16;286(50):43588.

46.

Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays.

Clemmons DR.

Clin Chem. 2011 Apr;57(4):555-9. doi: 10.1373/clinchem.2010.150631. Epub 2011 Feb 1.

47.

Clinical laboratory indices in the treatment of acromegaly.

Clemmons DR.

Clin Chim Acta. 2011 Feb 20;412(5-6):403-9. doi: 10.1016/j.cca.2010.11.008. Epub 2010 Nov 12. Review.

PMID:
21075098
48.

Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells.

Cascella T, Radhakrishnan Y, Maile LA, Busby WH Jr, Gollahon K, Colao A, Clemmons DR.

Endocrinology. 2010 Dec;151(12):5851-64. doi: 10.1210/en.2010-0350. Epub 2010 Sep 29.

49.

IGF-1 and bone: New discoveries from mouse models.

Yakar S, Courtland HW, Clemmons D.

J Bone Miner Res. 2010 Dec;25(12):2543-52. doi: 10.1002/jbmr.234. Review. Erratum in: J Bone Miner Res. 2011 Feb;26(2):439.

50.

Glucose regulation of thrombospondin and its role in the modulation of smooth muscle cell proliferation.

Maile LA, Allen LB, Hanzaker CF, Gollahon KA, Dunbar P, Clemmons DR.

Exp Diabetes Res. 2010;2010. pii: 617052. doi: 10.1155/2010/617052. Epub 2010 Jun 20.

Supplemental Content

Loading ...
Support Center